Form 4: Akebia Therapeutics Director Steven C. Gilman Receives Stock Options and Restricted Stock Units

Director Steven C. Gilman received 30,000 restricted stock units and options to purchase 45,000 shares of Akebia Therapeutics common stock on June 6, 2024.

Summary

• On June 6, 2024, Steven C. Gilman, a director of Akebia Therapeutics, Inc., was granted 30,000 restricted stock units (RSUs) and an option to purchase 45,000 shares of common stock.
• The RSUs and stock options were granted under the company's 2023 Stock Incentive Plan and the Third Amended and Restated Non-Employee Director Compensation Program.
• The RSUs will vest fully on the first anniversary of the grant date, or earlier if the first annual meeting of stockholders occurs before that date, contingent upon Gilman's continued service.
• The stock option, with an exercise price of $1.07, also vests fully on the first anniversary of the grant date, or earlier if the first annual meeting of stockholders occurs before that date, contingent upon Gilman's continued service.
• Following these transactions, Gilman directly owns 117,130 shares of Akebia Therapeutics common stock and options to purchase 45,000 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain qualified directors and align their interests with those of the shareholders.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning director interests with company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates